▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2937 by analyst upside · 2026-09-28
PCRX
Pacira BioSciences, Inc.
Healthcare · Market Cap $1B · P/E 71.8x
ANALYST PRICE TARGET
+19.4%
implied upside to consensus target
Current Price $25.12
Consensus Target $30.0
Bull Target $38.0
Bear Target $23.0
Analysts Covering 9
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
4
Hold
3
Sell
1
52-Week Low $18.8
52-Week High $27.66
YTD Return +2.7%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) 71.8x
Forward P/E 7.3x
EPS (TTM) $0.35
PEG Ratio 0.68
Dividend Yield N/A
Revenue (TTM) $746M
Profit Margin 2.0%
52-WEEK RANGE
52-Week Low $18.8
52-Week High $27.66
Current Price $25.12
Bear Target $23.0
Bull Target $38.0
● Now $25.12 ● Target $30.0
TRADING DATA
Avg Volume 574K
YTD Return +2.7%
Analyst Count 9
Consensus Buy
Upside to Target +19.4%
Last Updated 2026-09-28

ANALYST SUMMARY

Pacira BioSciences, Inc. (PCRX) is currently trading at $25.12 with a Wall Street consensus price target of $30.0, implying potential upside of 19.4% over the next 12 months. 9 analysts currently cover PCRX, with a consensus rating of Buy - 56% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $38.0, while the most cautious has a target of $23.0.

PCRX operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 2.7% year-to-date and is currently trading near the upper end of its 52-week range of $18.8 – $27.66.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

PNTG +14.5%
The Pennant Group, Inc.
$1B · P/E 44.8x · Buy
NRC +32.9%
NRC Health
$433M · P/E 81.5x · Strong Buy
BVS +27.4%
Bioventus Inc.
$943M · P/E 17.7x · Buy
CNMD +0.3%
CONMED Corporation
$1B · P/E 24.8x · Hold
INMD +13.4%
InMode Ltd.
$821M · P/E 11.8x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for PCRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Oppenheimer ● Initiated
Outperform 2026-09-23 14% win rate (7 calls)
Leerink Partners ● Initiated
Market Perform 2026-09-09 29% win rate (7 calls)
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-08-05 Building track record
Needham - Reiterated
Buy → Buy 2026-08-05 20% win rate (5 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-07-01 31% win rate (48 calls)
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-05-01 Building track record
Needham - Reiterated
Buy → Buy 2026-05-01 20% win rate (5 calls)
Barclays - Reiterated
Equal-Weight → Equal-Weight 2026-03-26 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
43
out of 100
Coverage depth
18/30
Consensus clarity
18/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →